Egetis
@egetis.com
Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.
Egetis's Company Logos
Egetis's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#007B9D
Allports
0, 123, 157
193, 100, 31
100, 22, 0, 38
#1E2C50
Cloud Burst
30, 44, 80
223, 45, 22
62, 45, 0, 69
#666666
Dove Gray
102, 102, 102
0, 0, 40
0, 0, 0, 60
#59A1DA
Havelock Blue
89, 161, 218
207, 64, 60
59, 26, 0, 15
About Egetis
Egetis Therapeutics is an innovative and integrated pharmaceutical company that focuses on developing treatments for serious diseases with significant unmet medical needs in the orphan drug segment. Their lead candidate, Emcitate, is a potential treatment for patients with monocarboxylate transporter 8 (MCT8) deficiency, a rare disease without currently available treatment options. Emcitate has shown highly significant and clinically relevant results in previous studies, and the company plans to submit a marketing authorization application (MAA) to the European Medicines Agency (EMA) in the second quarter of 2023.
In the US, Egetis will conduct a small study to verify the results and plans to submit a new drug application (NDA) in the second half of 2023. Emcitate is also being investigated in a Phase II/III study for younger MCT8 deficiency patients. Egetis also has a drug candidate called Aladote, which aims to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose.
Egetis Therapeutics is listed on the Nasdaq Stockholm main market
Related Brands
Tags
Orphan drug development
Late-stage pharmaceutical commercialization
MCT8 deficiency therapy
Tiratricol (Emcitate)
Paracetamol overdose liver injury therapy
